Review
doi: 10.1002/cmdc.202100395. Epub 2021 Aug 21.25CN-NBOH: A Selective Agonist for in vitro and in vivo Investigations of the Serotonin 2A Receptor
Affiliations
- PMID:34288515
- DOI: 10.1002/cmdc.202100395
Item in Clipboard
Review
25CN-NBOH: A Selective Agonist for in vitro and in vivo Investigations of the Serotonin 2A Receptor
Emil Märcher Rørsted et al. ChemMedChem..
Display options
Format
Display options
Format
Abstract
4-(2-((2-hydroxybenzyl)amino)ethyl)-2,5-dimethoxybenzonitrile (25CN-NBOH) was first reported as a potent and selective serotonin 2A receptor (5-HT2A R) agonist in 2014, and it has since found extensive use as a pharmacological tool in a variety of in vitro, ex vivo and in vivo studies. 25CN-NBOH is readily available from a synthetic perspective using standard chemical transformations, and displays favorable physiochemical properties in terms of stability and solubility. Due to its superior selectivity for 5-HT2A R, 25CN-NBOH has been used to investigate the effects of selective 5-HT2A R activation in vivo, and has thus become an important pharmacological tool for the exploration of 5-HT2A R signaling in a range of animal models. In the present review, we outline the discovery of 25CN-NBOH, its pharmacological profile and major findings from studies where it has been used.
Keywords: 5-HT2A; Serotonin; agonist; psychedelics; selectivity.
© 2021 Wiley-VCH GmbH.
Similar articles
- Detailed Characterization of the In Vitro Pharmacological and Pharmacokinetic Properties ofN-(2-Hydroxybenzyl)-2,5-Dimethoxy-4-Cyanophenylethylamine (25CN-NBOH), a Highly Selective and Brain-Penetrant 5-HT2A Receptor Agonist.Jensen AA, McCorvy JD, Leth-Petersen S, Bundgaard C, Liebscher G, Kenakin TP, Bräuner-Osborne H, Kehler J, Kristensen JL.Jensen AA, et al.J Pharmacol Exp Ther. 2017 Jun;361(3):441-453. doi: 10.1124/jpet.117.239905. Epub 2017 Mar 30.J Pharmacol Exp Ther. 2017.PMID:28360333
- The selective 5-HT2A receptor agonist 25CN-NBOH: Structure-activity relationship, in vivo pharmacology, and in vitro and ex vivo binding characteristics of [3H]25CN-NBOH.Jensen AA, Halberstadt AL, Märcher-Rørsted E, Odland AU, Chatha M, Speth N, Liebscher G, Hansen M, Bräuner-Osborne H, Palner M, Andreasen JT, Kristensen JL.Jensen AA, et al.Biochem Pharmacol. 2020 Jul;177:113979. doi: 10.1016/j.bcp.2020.113979. Epub 2020 Apr 13.Biochem Pharmacol. 2020.PMID:32298690
- Chronic treatment with a metabotropic mGlu2/3 receptor agonist diminishes behavioral response to a phenethylamine hallucinogen.Halberstadt AL, van der Zee JVF, Chatha M, Geyer MA, Powell SB.Halberstadt AL, et al.Psychopharmacology (Berl). 2019 Feb;236(2):821-830. doi: 10.1007/s00213-018-5118-y. Epub 2018 Nov 17.Psychopharmacology (Berl). 2019.PMID:30448990Free PMC article.
- "Selective" serotonin 5-HT2A receptor antagonists.Casey AB, Cui M, Booth RG, Canal CE.Casey AB, et al.Biochem Pharmacol. 2022 Jun;200:115028. doi: 10.1016/j.bcp.2022.115028. Epub 2022 Apr 4.Biochem Pharmacol. 2022.PMID:35381208Free PMC article.Review.
- Overcoming Depression with 5-HT2A Receptor Ligands.Zięba A, Stępnicki P, Matosiuk D, Kaczor AA.Zięba A, et al.Int J Mol Sci. 2021 Dec 21;23(1):10. doi: 10.3390/ijms23010010.Int J Mol Sci. 2021.PMID:35008436Free PMC article.Review.
Cited by
- 5-hydroxytryptamine 2C/1A receptors modulate the biphasic dose response of the head twitch response and locomotor activity induced by DOM in mice.Zhu H, Wang L, Wang X, Yao Y, Zhou P, Su R.Zhu H, et al.Psychopharmacology (Berl). 2024 Nov;241(11):2315-2330. doi: 10.1007/s00213-024-06635-4. Epub 2024 Jun 25.Psychopharmacology (Berl). 2024.PMID:38916640
- Identification of 5-HT2A receptor signaling pathways associated with psychedelic potential.Wallach J, Cao AB, Calkins MM, Heim AJ, Lanham JK, Bonniwell EM, Hennessey JJ, Bock HA, Anderson EI, Sherwood AM, Morris H, de Klein R, Klein AK, Cuccurazzu B, Gamrat J, Fannana T, Zauhar R, Halberstadt AL, McCorvy JD.Wallach J, et al.Nat Commun. 2023 Dec 15;14(1):8221. doi: 10.1038/s41467-023-44016-1.Nat Commun. 2023.PMID:38102107Free PMC article.
- Discovery and Structure-Activity Relationships of 2,5-Dimethoxyphenylpiperidines as Selective Serotonin 5-HT2A Receptor Agonists.M Ro Rsted E, Jensen AA, Smits G, Frydenvang K, Kristensen JL.M Ro Rsted E, et al.J Med Chem. 2024 May 9;67(9):7224-7244. doi: 10.1021/acs.jmedchem.4c00082. Epub 2024 Apr 22.J Med Chem. 2024.PMID:38648420Free PMC article.
- Introducing Conformational Restraints on 25CN-NBOH: A Selective 5-HT2A Receptor Agonist.Marcher-Rørsted E, Nykodemová J, Harpsøe K, Jensen AA, Kristensen JL.Marcher-Rørsted E, et al.ACS Med Chem Lett. 2023 Feb 20;14(3):319-325. doi: 10.1021/acsmedchemlett.3c00014. eCollection 2023 Mar 9.ACS Med Chem Lett. 2023.PMID:36923922Free PMC article.
- Discovery of β-Arrestin-Biased 25CN-NBOH-Derived 5-HT2A Receptor Agonists.Poulie CBM, Pottie E, Simon IA, Harpsøe K, D'Andrea L, Komarov IV, Gloriam DE, Jensen AA, Stove CP, Kristensen JL.Poulie CBM, et al.J Med Chem. 2022 Sep 22;65(18):12031-12043. doi: 10.1021/acs.jmedchem.2c00702. Epub 2022 Sep 13.J Med Chem. 2022.PMID:36099411Free PMC article.
References
- T. A. Mestre, M. Zurowski, S. H. Fox, Expert Opin. Invest. Drugs 2013, 22, 411-421.
- F. X. Vollenweider, K. H. Preller, Nat. Rev. Neurosci. 2020, 21, DOI 10.1038/s41583-020-0367-2.
- A. A. Jensen, J. D. McCorvy, S. L. Petersen, C. Bundgaard, G. Liebscher, T. P. Kenakin, H. Brauner-Osborne, J. Kehler, J. L. Kristensen, J. Pharmacol. Exp. Ther. 2017, 361, 441-453.
- R. R. Griffiths, M. W. Johnson, M. A. Carducci, A. Umbricht, W. A. Richards, B. D. Richards, M. P. Cosimano, M. A. Klinedinst, J. Psychopharmacol. 2016, 30, 1181-1197.
- R. L. Carhart-Harris, M. Bolstridge, J. Rucker, C. M. J. Day, D. Erritzoe, M. Kaelen, M. Bloomfield, J. A. Rickard, B. Forbes, A. Feilding, D. Taylor, S. Pilling, V. H. Curran, D. J. Nutt, The Lancet Psychiatry 2016, 3, 619-627.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources